Exact Mass: 395.02457580000004
Exact Mass Matches: 395.02457580000004
Found 64 metabolites which its exact mass value is equals to given mass value 395.02457580000004,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Cefdinir
C14H13N5O5S2 (395.03580880000004)
Cefdinir (marketed by Abbott Laboratories under the brand name Omnicef) is a semi-synthetic, broad-spectrum antibiotic in the third generation of the cephalosporin class, proven effective for common bacterial infections of the ear, sinus, throat, and skin. It was approved by the U.S. Food and Drug Administration (FDA) in December of 1997. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DD - Third-generation cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic
Pyranopterin
C10H14N5O6PS2 (395.01231140000004)
Oxaliplatin
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility. Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin®.
5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester, (4R)-
C18H13ClF3N3O2 (395.06483440000005)
Imidodicarbonimidic diamide, N-(1-methylethyl)-N'-(3-(2,4,5-trichlorophenoxy)propoxy)-, hydrochloride
C14H20Cl3N5O2 (395.06825100000003)
N-[1,3-Dimethyl-2,4-dioxo-6-(methylthio)-1,2,3,4-tetrahydrothieno[3,2-g]pteridine-7-ylcarbonyl]glycine
C14H13N5O5S2 (395.03580880000004)
cefdinir
C14H13N5O5S2 (395.03580880000004)
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DD - Third-generation cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams A cephalosporin compound having 7beta-2-(2-amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino- and 3-vinyl side groups. C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic It is used as a food additive .
6-(3-chloropropoxy)-N- (3-chloro-4-fluorophenyl)-7-Methoxyquinazolin-4-aMine
C18H16Cl2FN3O2 (395.06035479999997)
tert-butyl 7-bromo-4-oxospiro[3H-chromene-2,4-piperidine]-1-carboxylate
C18H22BrNO4 (395.07321120000006)
3-(4-chlorophenyl)sulfanyl-4-ethylsulfonyl-7-methoxy-2-methyl-1H-indole
2-(4-nitrophenyl)-3-(4-nitrophenyl)sulfonyl-1,3-thiazolidine
C15H13N3O6S2 (395.02457580000004)
tert-Butyl 6-bromo-4-oxospiro[chroman-2,4-piperidine]-1-carboxylate
C18H22BrNO4 (395.07321120000006)
(R)-2-(((BENZYLOXY)CARBONYL)AMINO)BUTANE-1,4-DIYL DIMETHANESULFONATE
Octanenitrile,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluoro-
(S)-1,1-binaphthyl-2,3-disulfoniMide
C20H13NO4S2 (395.02859780000006)
5-[3-(TERT-BUTYL)-1-(2,4-DICHLOROBENZYL)-1H-PYRAZOL-5-YL]-4-METHYL-4H-1,2,4-TRIAZOLE-3-THIOL
C17H19Cl2N5S (395.07381540000006)
5-(4-chlorophenoxy)-3-[3-(trifluoromethyl)phenyl]-1,2,4-triazine-6-carboxylic acid
Imidodicarbonimidic diamide, N-(1-methylethyl)-N-(3-(2,4,5-trichlorophenoxy)propoxy)-, hydrochloride
C14H20Cl3N5O2 (395.06825100000003)
D007004 - Hypoglycemic Agents > D001645 - Biguanides
2,7-Dihydroxy-1,3,2-benzodioxabismole-5-carboxylic acid
D006401 - Hematologic Agents > D003029 - Coagulants > D006490 - Hemostatics C254 - Anti-Infective Agent > C28394 - Topical Anti-Infective Agent D000890 - Anti-Infective Agents
5-Iodo-5,6-dihydro-6-azatubercidin
C10H14IN5O4 (395.00905140000003)
Keflin
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
5-[(2-Fluorophenyl)methyl]-6,11-dioxo-3-benzo[b][1,4]benzothiazepinecarboxylic acid
C21H14FNO4S (395.06275360000006)
4-(2,4-Dichlorophenoxy)butanoic acid [2-oxo-2-[(phenylmethyl)amino]ethyl] ester
C19H19Cl2NO4 (395.06910740000006)
N-[4-[(4-sulfamoylphenyl)sulfamoyl]phenyl]cyclopropanecarboxamide
1-[4-Chloro-3-(4-morpholinylsulfonyl)phenyl]-3-phenylurea
C17H18ClN3O4S (395.07064980000007)
N-[6-(diethylsulfamoyl)-1,3-benzothiazol-2-yl]-2-thiophenecarboxamide
C16H17N3O3S3 (395.04320120000006)
4-(2,4-dichlorophenoxy)-N-[(1E)-(3-nitrophenyl)methylene]butanohydrazide
C17H15Cl2N3O4 (395.04395700000003)
1,3-Benzothiazole-6-carboxylic acid [2-[(3,5-dichloro-4-methyl-2-pyridinyl)amino]-2-oxoethyl] ester
C16H11Cl2N3O3S (394.98981560000004)
[(3-methoxy-4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)carbonyl]{[2-(trifluoromethoxy)phenyl]sulfonyl}azanide
4-chloro-N-(3,5-dihydroxy-2-methylindol-1-yl)-3-sulfamoylbenzamide
C16H14ClN3O5S (395.03426640000004)
2-(4-bromophenyl)-N-[(2-chloro-3,4-dimethoxyphenyl)methyl]-1-cyclopropanamine
4-chloro-N-[(2S)-5-hydroxy-2-methyl-3-oxo-2H-indol-1-yl]-3-sulfamoylbenzamide
C16H14ClN3O5S (395.03426640000004)
3-(3-Bromo-4-hydroxyphenyl)-9-methyl-5,9,14-triazatetracyclo[6.6.1.02,6.011,15]pentadeca-1(14),2(6),3,8(15),10-pentaen-7-one
LY3020371 (hydrochloride)
C15H16ClF2NO5S (395.04057400000005)
LY3020371 hydrochloride is a potent, selective metabotropic glutamate 2/3 receptor (mGlu2/3) antagonist with Ki of 5.3 and 2.5 nM, potently blocks cAMP formation with IC50 of 16.2 nM[1]. LY3020371 hydrochloride exerts an antidepressant-like signature in vivo[2].
MMRi62
MMRi62, a ferroptosis inducer targeting MDM2-MDM4 (negative regulators of tumor suppressor p53). MMRi62 shows a P53-independent pro-apoptotic activity against pancreatic ductal adenocarcinoma (PDAC) cells and induce autophagy. MMRi62 inducesferroptosis, resulting in a increase of reactive oxygen and lysosomal degradation of ferritin heavy chain (FTH1). MMRi62 also leads to proteasomal degradation of mutant p53, also inhibits orthotopic xenograft PDAC mouse model in vivo with high frequency mutation characteristics of KRAS and TP53.12[1][2].
[2-hydroxy-4-(4-hydroxy-2-imino-5,8-dihydro-1h-pteridin-6-yl)-3,4-disulfanylbut-3-en-1-yl]oxyphosphonic acid
C10H14N5O6PS2 (395.01231140000004)
[(3e)-2-hydroxy-4-(4-hydroxy-2-imino-5,8-dihydro-1h-pteridin-6-yl)-3,4-disulfanylbut-3-en-1-yl]oxyphosphonic acid
C10H14N5O6PS2 (395.01231140000004)
(6r,7r)-3-ethenyl-7-{[(2z)-1-hydroxy-2-(hydroxyimino)-2-(2-imino-3h-1,3-thiazol-4-yl)ethylidene]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
C14H13N5O5S2 (395.03580880000004)